<DOC>
	<DOCNO>NCT00292084</DOCNO>
	<brief_summary>This extension study HCV-05-002 . The objective study evaluate safety efficacy celgosivir plus peginterferon alfa-2b , without ribavirin , additional 36 week patient chronic hepatitis C genotype 1 infection .</brief_summary>
	<brief_title>An Extension Study Evaluate Safety Efficacy Celgosivir Peginterferon Alfa-2b , With Without Ribavirin , Patients With Chronic Hepatitis C Genotype 1 Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patients complete HCV05002 1865 year age , inclusive Primary diagnosis chronic HCV infection Nonresponders previous pegylated interferonbased therapy Patients naive interferonbased therapy chronic HCV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Celgosivir</keyword>
	<keyword>HCV</keyword>
	<keyword>Genotype 1</keyword>
	<keyword>Non-responders</keyword>
	<keyword>End Treatment Response</keyword>
	<keyword>Sustained Viral Response</keyword>
</DOC>